AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8076565 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedures performed by the most experienced endoscopist
Number of subjects: 130
Study 8076565 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison (female vs male patients)
Number of subjects: 130
Study 2707713 — intervention group
Group type: EXPERIMENTAL
Intervention: Posturographic biofeedback training
Number of subjects: 72
Study 2707713 — intervention group
Group type: COMPARATOR
Intervention: Physical training (control group)
Number of subjects: 72
Study 336132 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-layer closure (continuous catgut to peritoneum and continuous nylon to sheath)
Number of subjects: 326
Study 336132 — intervention group
Group type: COMPARATOR
Intervention: One-layer closure (peritoneal suture line omitted)
Number of subjects: 326
Study 336132 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with jaundice
Number of subjects: 326
Study 336132 — intervention group
Group type: COMPARATOR
Intervention: Non-jaundiced patients
Number of subjects: 326
Study 29677687 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma from women with late onset preeclampsia
Number of subjects: 3
Study 29677687 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma from women with gestational hypertension (GH)
Number of subjects: 3
Study 29677687 — intervention group
Group type: COMPARATOR
Intervention: Plasma from women after normotensive pregnancy
Number of subjects: 3
Study 29677687 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥25
Number of subjects: 3
Study 28045554 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (27 sessions over nine weeks)
Number of subjects: 19
Study 28045554 — intervention group
Group type: COMPARATOR
Intervention: Social/art activities (control group)
Number of subjects: 19
Study 26362236 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandal orthotic
Number of subjects: 52
Study 26362236 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandal
Number of subjects: 52
Study 26362236 — intervention group
Group type: COMPARATOR
Intervention: Footwear conditions
Number of subjects: 52
Study 22305632 — intervention group
Group type: EXPERIMENTAL
Intervention: ERN/LRPT 1g/20mg + SIMVA (10 or 20mg)
Number of subjects: 2340
Study 22305632 — intervention group
Group type: COMPARATOR
Intervention: ATORVA (10, 20, 40, or 80 mg)
Number of subjects: 2340
Study 21986305 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 40
Study 21986305 — intervention group
Group type: COMPARATOR
Intervention: Side‐posture positioning only (control)
Number of subjects: 40
Study 18276803 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 0.14 mg/kg
Number of subjects: 45
Study 18276803 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 0.3 mg/kg
Number of subjects: 45
Study 18276803 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 10 mg
Number of subjects: 45
Study 16467761 — intervention group
Group type: EXPERIMENTAL
Intervention: Single immediate dose of Mitomycin C (MMC)
Number of subjects: 100
Study 16467761 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed multi-dose regimen of Mitomycin C (MMC)
Number of subjects: 100
Study 12830442 — intervention group
Group type: EXPERIMENTAL
Intervention: Short daily HD
Number of subjects: 45
Study 12830442 — intervention group
Group type: EXPERIMENTAL
Intervention: Long nocturnal HD
Number of subjects: 45
Study 12830442 — intervention group
Group type: COMPARATOR
Intervention: Conventional thrice-weekly HD
Number of subjects: 45
Study 12830442 — intervention group
Group type: EXPERIMENTAL
Intervention: Quotidian HD therapy
Number of subjects: 45
Study 10706488 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose inhaled steroids
Number of subjects: 619
Study 10706488 — intervention group
Group type: COMPARATOR
Intervention: Low dose inhaled steroids
Number of subjects: 619
Study 10706488 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated IgG and/or IgA
Number of subjects: 619
Study 10706488 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated IgA
Number of subjects: 619
Study 9322351 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg i.v. on day 1 + 2, then 10 mg p.o.
Number of subjects: 193
Study 9322351 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg i.v. on day 1 + 2, then 10 mg p.o. + Dexamethasone 20 mg i.v. on days 1 + 2, then 4 mg i.v./p.o.
Number of subjects: 193
Study 9322351 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg i.v. on day 1 + 2, then 10 mg p.o. + Metoclopramide 20 mg i.v. + 2 x 10 mg p.o. on day 1, then 3 x 10 mg p.o.
Number of subjects: 193
Study 29198307 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 25 mg film-coated tablets
Number of subjects: 24
Study 29198307 — intervention group
Group type: COMPARATOR
Intervention: Control formulation of quetiapine 25 mg film-coated tablets
Number of subjects: 24
Study 3947001 — intervention group
Group type: EXPERIMENTAL
Intervention: Endolymphatic sac-mastoid shunt surgery
Number of subjects: 0
Study 3947001 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery (simple mastoidectomy)
Number of subjects: 0
Study 3947001 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 30103738 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-facing decision aid, RealRisks, and provider-facing Breast Cancer Risk Navigation Toolbox (BNAV) with standard education
Number of subjects: 0
Study 30103738 — intervention group
Group type: COMPARATOR
Intervention: Standard education alone
Number of subjects: 0
Study 27855094 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 0
Study 27855094 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 24910976 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical rapamycin 0.1%
Number of subjects: 19
Study 24910976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 23278712 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH) at 33°C for 24 hours
Number of subjects: 31
Study 23278712 — intervention group
Group type: COMPARATOR
Intervention: Standardized stroke unit care (control)
Number of subjects: 31
Study 23278712 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular cooling
Number of subjects: 31
Study 23278712 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface cooling
Number of subjects: 31
Study 23278712 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH)
Number of subjects: 31
Study 20497031 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for 12 months
Number of subjects: 81
Study 20497031 — intervention group
Group type: COMPARATOR
Intervention: Sham-acupuncture for 6 months
Number of subjects: 81
Study 19133217 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (300 mg, once or twice per day)
Number of subjects: 0
Study 19133217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19133217 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 0
Study 19133217 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 0
Study 16364669 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-003 (200 mg, solution in distilled water)
Number of subjects: 16
Study 16364669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 14605526 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 20
Study 14605526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10978998 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilators
Number of subjects: 0
Study 10978998 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement
Number of subjects: 0
Study 10978998 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms, left ventricular function, and response to exercise
Number of subjects: 0
Study 8769499 — intervention group
Group type: COMPARATOR
Intervention: Nasal CPAP (C1)
Number of subjects: 6
Study 8769499 — intervention group
Group type: EXPERIMENTAL
Intervention: No CPAP (C2)
Number of subjects: 6
Study 8769499 — intervention group
Group type: EXPERIMENTAL
Intervention: No CPAP (AP2)
Number of subjects: 6
Study 8769499 — intervention group
Group type: COMPARATOR
Intervention: Nasal CPAP (C2)
Number of subjects: 6
Study 1564128 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-a-day therapy (i.v. dose: 0.8-33 mg/kg; oral dose: 1.6-66 mg/kg)
Number of subjects: 69
Study 1564128 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-day therapy (i.v. dose: 0.8-33 mg/kg; oral dose: 1.6-66 mg/kg)
Number of subjects: 69
Study 3544957 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (0.4 mg)
Number of subjects: 54
Study 3544957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular buprenorphine (0.3 mg)
Number of subjects: 54
Study 3544957 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular meperidine (75 mg)
Number of subjects: 54
Study 29500030 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab for RSV immunoprophylaxis
Number of subjects: 429
Study 29500030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 27265813 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to discussions about end-of-life care
Number of subjects: 473
Study 27265813 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitator - having had family/friends who died
Number of subjects: 473
Study 27265813 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitator - concerns about future quality of life
Number of subjects: 473
Study 27265813 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitator - worries about being a burden on friends/family
Number of subjects: 473
Study 27265813 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 473
Study 27265813 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 473
Study 24462230 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 82
Study 24462230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 82
Study 24462230 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram plus CBT
Number of subjects: 82
Study 24462230 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonresponders)
Number of subjects: 82
Study 24462230 — intervention group
Group type: COMPARATOR
Intervention: Whole-brain analysis
Number of subjects: 82
Study 22891236 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematically developed order set
Number of subjects: 7
Study 22891236 — intervention group
Group type: COMPARATOR
Intervention: Historical control (ad hoc developed order set)
Number of subjects: 7
Study 20955603 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, nutritional treatment with energy- and protein-rich supplementation
Number of subjects: 124
Study 20955603 — intervention group
Group type: COMPARATOR
Intervention: Routine nutritional care (control)
Number of subjects: 124
Study 18565087 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional faces
Number of subjects: 0
Study 18565087 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright emotional faces
Number of subjects: 0
Study 18565087 — intervention group
Group type: COMPARATOR
Intervention: Face stimuli
Number of subjects: 0
Study 16646970 — intervention group
Group type: EXPERIMENTAL
Intervention: One lottery scratch ticket worth 20 Norwegian kroner
Number of subjects: 1500
Study 16646970 — intervention group
Group type: EXPERIMENTAL
Intervention: Two lottery scratch tickets
Number of subjects: 1500
Study 16646970 — intervention group
Group type: EXPERIMENTAL
Intervention: Two scratch tickets promised if replied within one week
Number of subjects: 1500
Study 16646970 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 kroner banknote
Number of subjects: 1500
Study 16646970 — intervention group
Group type: COMPARATOR
Intervention: Control group (no incentive)
Number of subjects: 1500
Study 14653300 — intervention group
Group type: EXPERIMENTAL
Intervention: bleaching with gel + 10% sodium ascorbate (SA)
Number of subjects: 90
Study 14653300 — intervention group
Group type: EXPERIMENTAL
Intervention: bleaching with gel
Number of subjects: 90
Study 14653300 — intervention group
Group type: EXPERIMENTAL
Intervention: bleaching with sol + 10% sodium ascorbate
Number of subjects: 90
Study 14653300 — intervention group
Group type: EXPERIMENTAL
Intervention: bleaching with gel + 10% butylhydroxyanisole (BHA)
Number of subjects: 90
Study 14653300 — intervention group
Group type: EXPERIMENTAL
Intervention: bleaching with sol + 10% BHA
Number of subjects: 90
Study 14653300 — intervention group
Group type: EXPERIMENTAL
Intervention: bleaching with gel + immersed in artificial saliva for seven days
Number of subjects: 90
Study 14653300 — intervention group
Group type: EXPERIMENTAL
Intervention: bleaching with sol + immersed in artificial saliva for seven days
Number of subjects: 90
Study 14653300 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 90
Study 10995148 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 74
Study 10995148 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 74
Study 7763124 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (2 mg/kg) and intravenous saline (5 mL/kg)
Number of subjects: 34
Study 7763124 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal saline (2 mL) and intravenous 10% ethanol (5 mL/kg)
Number of subjects: 34
Study 7763124 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (2 mg/kg) and intravenous 10% ethanol (5 mL/kg)
Number of subjects: 34
Study 7763124 — intervention group
Group type: COMPARATOR
Intervention: Intranasal (2 mL) and intravenous (5 mL/kg) saline
Number of subjects: 34
Study 2106127 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide treatment with high phosphorus intake (1.64 +/- 0.06 mmol/kg per day)
Number of subjects: 16
Study 2106127 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide treatment with moderate phosphorus intake (1.24 +/- 0.02 mmol/kg per day)
Number of subjects: 16
Study 2106127 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide treatment with low phosphorus intake (0.91 +/- 0.06 mmol/kg per day)
Number of subjects: 16
Study 2106127 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide treatment
Number of subjects: 16
Study 2106127 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with furosemide) with moderate phosphorus intake (1.24 +/- 0.02 mmol/kg per day)
Number of subjects: 16
Study 2106127 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with furosemide) with low phosphorus intake (0.91 +/- 0.06 mmol/kg per day)
Number of subjects: 16
Study 509829 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic glucose (A)
Number of subjects: 64
Study 509829 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (B)
Number of subjects: 64
Study 509829 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 64
Study 31985602 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.1 mmol/kg body weight)
Number of subjects: 15
Study 31985602 — intervention group
Group type: COMPARATOR
Intervention: Gadoteridol (0.1 mmol/kg body weight)
Number of subjects: 15
Study 31985602 — intervention group
Group type: COMPARATOR
Intervention: Gadoterate meglumine (0.1 mmol/kg body weight)
Number of subjects: 15
Study 31985602 — intervention group
Group type: EXPERIMENTAL
Intervention: All GBCAs
Number of subjects: 15
Study 31985602 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Number of subjects: 15
Study 30720556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 342
Study 30720556 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 342
Study 28070861 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 2010
Study 28070861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2010
Study 26054881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinol‐10 (300 mg per day for 48 weeks)
Number of subjects: 28
Study 26054881 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 48 weeks)
Number of subjects: 28
Study 26054881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinol‐10 (300 mg per day for 96 weeks)
Number of subjects: 28
Study 26054881 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 96 weeks)
Number of subjects: 28
Study 23810276 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin/olmesartan 20/40 mg (test formulation)
Number of subjects: 58
Study 23810276 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 20 mg and olmesartan 40 mg (reference formulation)
Number of subjects: 58
Study 21592475 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine in the third trimester and postpartum antiviral treatment
Number of subjects: 70
Study 21592475 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum lamivudine (n = 16) or entecavir (n = 10)
Number of subjects: 70
Study 21592475 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment only)
Number of subjects: 70
Study 19848566 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored feedback based on cholesterol-related knowledge, attitudes, beliefs, and perceived barriers to medication adherence; 2 additional tailored IVR support calls.
Number of subjects: 497
Study 19848566 — intervention group
Group type: COMPARATOR
Intervention: Generic feedback and a generic cholesterol guide.
Number of subjects: 497
Study 16964510 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Number of subjects: 43
Study 16964510 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood culture
Number of subjects: 43
Study 16964510 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF culture
Number of subjects: 43
Study 16964510 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined culture and Gram stain
Number of subjects: 43
Study 16964510 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 43
Study 15090314 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard heparin
Number of subjects: 103
Study 15090314 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 103
Study 15090314 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-molecular-weight dextran)
Number of subjects: 103
Study 10859723 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-based radiation with Ir-192
Number of subjects: 55
Study 10859723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 9303024 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Number of subjects: 54
Study 8251027 — intervention group
Group type: EXPERIMENTAL
Intervention: DL473 twice‐weekly (2HE+L2/7H2L2)
Number of subjects: 267
Study 8251027 — intervention group
Group type: EXPERIMENTAL
Intervention: ARFp twice‐weekly (2HE+R2/7H2R2)
Number of subjects: 267
Study 8251027 — intervention group
Group type: COMPARATOR
Intervention: BRFP daily (2HRE/7HR)
Number of subjects: 267
Study 2883223 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytetracycline lavage alone
Number of subjects: 84
Study 2883223 — intervention group
Group type: COMPARATOR
Intervention: Oxytetracycline lavage plus peroperative intravenous metronidazole and cefuroxime
Number of subjects: 84
Study 29265793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac 75 mg + thiocolchicoside 4 mg (FDC)
Number of subjects: 223
Study 29265793 — intervention group
Group type: COMPARATOR
Intervention: Separate injection of diclofenac and thiocolchicoside (reference)
Number of subjects: 223
Study 29265793 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and reference treatments
Number of subjects: 223
Study 26250745 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 236
Study 26250745 — intervention group
Group type: COMPARATOR
Intervention: Expressive Writing
Number of subjects: 236
Study 26250745 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list Control
Number of subjects: 236
Study 23878833 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.5% hydrofluoric acid (HF) conditioning
Number of subjects: 45
Study 23878833 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribochemical silica coating (TS) conditioning
Number of subjects: 45
Study 23878833 — intervention group
Group type: COMPARATOR
Intervention: Control group (unconditioned)
Number of subjects: 45
Study 23737940 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg zinc plus riboflavin 0.5 mg/day)
Number of subjects: 324
Study 23737940 — intervention group
Group type: COMPARATOR
Intervention: Placebo (riboflavin 0.5 mg/day)
Number of subjects: 324
Study 20568431 — intervention group
Group type: EXPERIMENTAL
Intervention: Embedding thread at Shenshu (BL 23)
Number of subjects: 70
Study 20568431 — intervention group
Group type: COMPARATOR
Intervention: Medication group
Number of subjects: 70
Study 18802808 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor's consultation (Group 2 and Group 3)
Number of subjects: 308
Study 18802808 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototest (Group 3)
Number of subjects: 308
Study 18802808 — intervention group
Group type: COMPARATOR
Intervention: Letter feedback (Group 1)
Number of subjects: 308
Study 16631127 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of alprazolam
Number of subjects: 16
Study 16631127 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of alprazolam
Number of subjects: 16
Study 16631127 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of diphenhydramine (Benadryl)
Number of subjects: 16
Study 16631127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16631127 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of alprazolam (1 mg)
Number of subjects: 16
Study 12847155 — intervention group
Group type: EXPERIMENTAL
Intervention: AN1792 (aggregated Abeta42)
Number of subjects: 372
Study 12847155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 10333379 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg QD)
Number of subjects: 24